Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;25(6):841-5.
doi: 10.3346/jkms.2010.25.6.841. Epub 2010 May 24.

High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia

Hyoung Jin Kang  1 , Ji Won Lee, Sang Hyeok Kho, Min Jeong Kim, Young Jin Seo, Hyery Kim, Hee Young Shin, Hyo Seop Ahn
Affiliations

High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia

Hyoung Jin Kang et al. J Korean Med Sci. 2010 Jun.

Abstract

Identification of prognostic factors and risk-based post-remission therapy was proposed to improve the outcomes of acute myeloid leukemia (AML) and a mutation of FLT3 has been reported to be a risk factor, especially for pediatric patients. Recently, FLT3 expression level was implicated to have prognostic significance in adults, but little is known for childhood AML. To define the prognostic significance, transcript level of FLT3 was analyzed in 52 pediatric AML patients. The median copy number of FLT3 was 4.6x10(3) (40-5.9x10(7) copies)/1.0x10(6) GAPDH copy, and the relapse free survival of patients with high transcript level of FLT3 (>10(6) copy number) (0%) was significantly lower than that of the others (53.2%). High transcript level of FLT3 was associated with a markedly high risk of relapse. The development of new therapeutic scheme such as a frontline allogeneic stem cell transplantation or administration of FLT3 inhibitor is needed to improve outcomes.

Keywords: FLT3; Leukemia, Myeloid, Acute; Pediatric Age; Transcript Level.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The relapse free survival (RFS) of patients with high transcript level of FLT3 (0%) was lower than the RFS of the other patients (53.2±8.0%) (P<0.001).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rowe JM, Tallman MS. Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged? Blood. 1997;90:2121–2126. - PubMed
    1. Amadori S, Testi AM, Aricò M, Comelli A, Giuliano M, Madon E, Masera G, Rondelli R, Zanesco L, Mandelli F The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol. 1993;11:1046–1054. - PubMed
    1. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J, Carroll A, Inoue S, Camitta B, Weinstein HJ Pediatric Oncology Group. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med. 1996;334:1428–1434. - PubMed
    1. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, Dusenbery K, DeSwarte J, Arthur DC, Lange BJ, Kobrinsky NL Children's Cancer Group. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97:56–62. - PubMed
    1. Meshinchi S, Arceci RJ. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist. 2007;12:341–355. - PubMed

Publication types

Substances